loading page

Pharmaceutical Payments to Japanese Certificated Pediatric Hematologist/Oncologists: a cross-sectional analysis of personal payments from pharmaceutical companies between 2016 and 2019
  • +6
  • Eiji Kusumi,
  • Anju Murayama,
  • Sae Kamamoto,
  • Makoto Yoshida,
  • Hiroaki Saito,
  • Toyoaki Sawano,
  • Erika Yamashita,
  • Tetsuya Tanimoto,
  • Akihiko Ozaki
Eiji Kusumi
Navitas Clinic Shinzyuku

Corresponding Author:[email protected]

Author Profile
Anju Murayama
Medical Governance Research Institute
Author Profile
Sae Kamamoto
Medical Governance Research Institute
Author Profile
Makoto Yoshida
Medical Governance Research Institute
Author Profile
Hiroaki Saito
Sendai Kosei Hospital
Author Profile
Toyoaki Sawano
Joban Hospital
Author Profile
Erika Yamashita
Medical Governance Research Institute
Author Profile
Tetsuya Tanimoto
Navitas Clinic
Author Profile
Akihiko Ozaki
Joban Hospital
Author Profile

Abstract

Among all pediatric hematologist-oncologists (PHOs) certificated by the Japanese Society of Pediatric Hematology/Oncology (JSPHO), 215 PHOs (70.0%) received $908,900 personal payments from 54 pharmaceutical companies between 2016 and 2019. Four-year combined average payments per author was $2,961 (standard deviation: $6,299). While the prevalence of physicians with payments was relatively stable during the study period with 40.4% and 44.6% in 2016 and 2019, the average annual personal payments increased nearly double from $559 in 2016 to $1,096 in 2019, respectively. Payments from the top five companies with the largest total payments accounted for 48.8% of total monetary values.
28 Dec 2021Submitted to Pediatric Blood & Cancer
28 Dec 2021Submission Checks Completed
28 Dec 2021Assigned to Editor
03 Jan 2022Reviewer(s) Assigned
10 Feb 2022Review(s) Completed, Editorial Evaluation Pending
10 Feb 2022Editorial Decision: Revise Major
14 Jun 2022Submission Checks Completed
14 Jun 2022Assigned to Editor
14 Jun 20221st Revision Received
22 Jun 2022Reviewer(s) Assigned
01 Jul 2022Review(s) Completed, Editorial Evaluation Pending
03 Jul 2022Editorial Decision: Accept